Every Form 4 that Mimedx Group Inc (MDXG) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow MDXG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MDXG filings page.
MIMEDX GROUP, INC. Chief Financial Officer Doug Rice reported an automatic share disposition related to tax obligations, rather than an open-market trade. On vesting of restricted stock units, 12,749 shares of common stock were withheld at $3.95 per share to cover tax liabilities. After this tax-withholding event, Rice directly holds 399,566 shares of MIMEDX common stock, indicating that the filing reflects routine compensation-related administration instead of a discretionary buy or sell decision.
MIMEDX GROUP, INC. Chief Commercial Officer Kimberly Maersk-Moller reported a compensation-related share transaction. On the vesting of restricted stock, 19,820 shares of common stock were withheld by the company at $3.83 per share to satisfy tax obligations.
This tax-withholding disposition is not an open-market sale and does not reflect a discretionary trade. After the withholding, Maersk-Moller holds 309,630 shares of MIMEDX common stock directly, showing she retains a substantial equity position in the company.
BIERMAN JAMES L reported acquisition or exercise transactions in this Form 4 filing.
MIMEDX GROUP, INC. director James L. Bierman received an annual restricted stock grant of 50,913 shares of common stock on June 10, 2026 at $3.64 per share. The award to this non-employee director vests upon the earlier of 12 months or the next meeting of shareholders, bringing his direct holdings to 263,684 shares. This is a compensation-related equity award, not an open-market purchase.
PUHY DOROTHY E reported acquisition or exercise transactions in this Form 4 filing.
MiMedx Group director Dorothy E. Puhy received a grant of 50,913 shares of common stock at $3.64 per share as an annual restricted stock award for non-employee directors. This compensation-related grant, exempt under Rule 16b-3, will vest upon the earlier of 12 months or the next shareholder meeting. Following the award, she directly holds 108,510 shares of MiMedx common stock.
MIMEDX GROUP, INC. director Todd Newton received an annual restricted stock award, acquiring 50,913 shares of common stock at a reference price of $3.64 per share as director compensation. The grant is exempt under Rule 16b-3 and will vest upon the earlier of 12 months or the next shareholder meeting. Following this award, Newton directly holds 463,684 shares of MIMEDX common stock.
HAWKINS WILLIAM A reported acquisition or exercise transactions in this Form 4 filing.
MIMEDX GROUP, INC. director William A. Hawkins received an annual restricted stock grant of 50,913 shares of common stock at $3.64 per share. This grant is compensation for his service as a non-employee director and is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next meeting of shareholders. Following this grant, Hawkins directly holds 254,931 shares of MIMEDX common stock.
Olson Tiffany reported acquisition or exercise transactions in this Form 4 filing.
MIMEDX GROUP, INC. director Tiffany Olson received an award of 50,913 shares of common stock at $3.64 per share as a restricted stock grant for non-employee directors. This equity award vests upon the earlier of 12 months or the next meeting of shareholders, and is exempt under Rule 16b-3. Following the grant, she directly holds 108,510 shares of common stock. This is a compensation-related equity grant rather than an open-market purchase.
MIMEDX GROUP, INC. General Counsel and Chief Administrative Officer William Frank Hulse IV reported a tax-related share disposition. On March 13, 2026, 20,245 shares of common stock were withheld at $4.38 per share to cover tax obligations on vesting of restricted stock. After this withholding, he directly holds 543,195 shares of MIMEDX common stock, indicating this was a routine compensation and tax event rather than an open-market trade.
MIMEDX GROUP, INC. Chief Commercial Officer Kimberly Maersk-Moller reported a routine tax-related share disposition. On March 13, 2026, 6,762 shares of common stock were withheld at $4.38 per share to cover tax obligations on vesting of restricted stock.
These shares were withheld by the company rather than sold in the open market. After this transaction, Maersk-Moller directly owned 329,450 shares of MiMedx common stock.
MIMEDX GROUP Chief Commercial Officer Kimberly Maersk-Moller reported compensation-related share activity. On this Form 4, 42,845 shares of common stock were acquired on March 10, 2026 through the vesting of performance stock units granted on March 13, 2023. Of these, 21,270 shares were withheld to cover tax obligations required by company policy, leaving her with 336,212 shares of common stock owned directly after the transactions.
MIMEDX GROUP General Counsel and CAO William Frank Hulse IV received common shares through the vesting of performance stock units at $4.50 per share. A portion of the vested shares was withheld to cover tax obligations, leaving him with 563,440 directly owned shares after these transactions.
MiMedx Group Chief Financial Officer Doug Rice reported equity compensation activity tied to performance stock units (PSUs). On the reported date, he acquired 243,000 shares of common stock at $4.50 per share upon vesting of PSUs covering the performance period from January 1, 2023 to December 31, 2025.
In connection with this vesting, 96,363 shares were disposed of at $4.50 per share to satisfy tax obligations, with shares withheld as required by company policy rather than sold on the open market. After these transactions, Rice directly held 412,315 shares of MiMedx common stock.
Capper Joseph H reported acquisition or exercise transactions in this Form 4 filing.
MiMedx Group, Inc. Chief Executive Officer Joseph H. Capper reported equity awards consisting of stock options and restricted stock granted on March 4, 2026. He was awarded 310,574 stock options and 371,094 shares of common stock at a price of $0.00 per share.
The restricted stock grant vests fully on the third anniversary of the grant date, subject to his continued employment under a Restricted Stock Unit Agreement. The stock options vest in four equal annual installments of 25% on each anniversary of the grant date, also subject to continued employment.
MiMedx Group Chief Financial Officer Doug Rice received new equity awards in the form of stock options and restricted stock. On March 4, 2026, he was granted 62,068 stock options at an exercise price of $0.00 per share and 74,163 shares of common stock as a restricted stock grant.
The stock options vest in four equal annual installments of 25% on each anniversary of the grant date, contingent on his continued employment under the Nonqualified Stock Option Agreement. The restricted stock vests fully on the third anniversary of the grant date, also subject to continued employment under the Restricted Stock Unit Agreement.
Hulse William Frank IV reported acquisition or exercise transactions in this Form 4 filing.
MIMEDX GROUP, INC. General Counsel and Chief Administrative Officer William Frank Hulse IV reported equity awards on Common Stock and Stock Options. These are classified as grants or awards rather than open‑market purchases or sales.
The filing shows an award of 74,987 shares of Common Stock at a price per share of $0.0000, bringing his directly held Common Stock to 488,536 shares. According to the footnotes, this represents restricted stock that vests fully on the third anniversary of the grant, subject to his continued employment under the Restricted Stock Unit Agreement.
He also received Stock Options covering 62,758 shares at a price per share of $0.0000, increasing his directly held options to 171,190. The options vest 25% on each anniversary of the grant date, conditioned on his continued employment as described in the Nonqualified Stock Option Agreement.
MIMEDX GROUP, INC. Chief Operating Officer Ricci S. Whitlow reported equity awards on March 4, 2026. She acquired 62,068 stock options and 74,163 shares of restricted common stock at a price of $0.00 per share as compensation grants.
The restricted stock vests fully on the third anniversary of the grant, subject to continued employment. The options vest in four equal annual installments, each 25% on the grant-date anniversaries, also conditioned on continued employment. Following these grants, she directly holds 169,309 stock options and 462,825 common shares.
MIMEDX GROUP, INC. Chief Commercial Officer Kimberly Maersk-Moller reported equity awards on March 4, 2026. She was granted 62,068 stock options at an exercise price of $0.00 per share, increasing her directly held options to 137,862 following the grant.
She also received a grant of 74,163 shares of common stock at $0.00 per share, raising her directly held common shares to 314,637. Footnotes state the common stock grant consists of restricted stock that vests fully on the third anniversary of the grant, and that the options vest in 25% increments on each anniversary of the grant date, in both cases conditioned on continued employment.
MiMedx Group Chief Operating Officer Ricci S. Whitlow reported a tax-related share disposition. On the vesting of restricted stock, 61,961 shares of common stock were withheld by the company to satisfy tax withholding requirements at $5.12 per share. After this transaction, Whitlow directly owns 388,662 shares of MiMedx Group common stock, which includes 1,675 shares previously acquired through the company’s Employee Stock Purchase Plan.
MiMedx Group (MDXG) reported an insider transaction by its Chief Commercial Officer, Kimberly Maersk‑Moller. On 11/06/2025, she sold 58,300 shares of common stock at a weighted average price of $7.4156 (Transaction Code: S). Following the sale, she beneficially owns 236,982 shares, held directly.
The price reflects multiple trades aggregated into a single weighted average. The reporting person has indicated she will provide full trade-by-trade pricing details upon request, as customary in such disclosures.